http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-602948-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_681ff6871f0118f0ac26adb6337c6bec |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 |
| filingDate | 2011-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4411f7d58d3472783fd4b2f765a58445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a0542a20b2c082614de18d7efac8800 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c87db13721d7cfaf8979a1bc0646f04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18b4c79abf7562097d107e2593094b0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a646851daf46e566bdc209051872e22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2983a4214de8ec482696468651bf850 |
| publicationDate | 2014-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-602948-A |
| titleOfInvention | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders |
| abstract | Disclosed are thieno[3,2-b]pyridine derivatives selected from 3-[(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl]-1-ethyl-3-[2-methoxyethyl]urea, N-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yI)methyl)-N-(2-methoxyethyl)formamide, N-((6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-b]pyridin-2-yl)-pyridin-3-yl)methyl)-N-(2-methoxyethyl)acetamide, 1-cyclopropyI-3-(3-fluoro-4-(2-(5-((4-(2-hydroxyacetyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea, (S)-2-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)-2-oxoethyl 2-amino-3-methylbutanoate, 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((2-(methylsulfonyl)ethylamino)methyl)pyridin-2-yl)thieno[3,2-b ]pyridin-7-yloxy)phenyl)urea, 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-((2-hydroxyethyl)(methyl)amino)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea, 1-((2-(7-(4-Isopropylaminocarbonylamino-2-fluorophenoxy)thieno[3,2-b ]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-3-isopropyl-1-(2-methoxyethyl)urea, N-((2-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-2-hydroxy-N-(2-methoxyethyl)acetamide, 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea and 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-morpholinoethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea. Further disclosed is a composition comprising a compound as defined above and a pharmaceutically acceptable carrier, for treating an ophthalmic disease, condition or disorder, wherein the ophthalmic disease, disorder or condition is selected from the group consisting of (a) a disease, disorder or condition caused by choroidal angiogenesis (including age-related macular degeneration), (b) diabetic retinopathy and (c) retinal edema. |
| priorityDate | 2010-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.